Targeting tumor‐associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Tumor-associated fibroblasts are key regulators of tumorigenesis. In contrast to tumor cells, which are genetically unstable and mutate frequently, the presence of genetically more stable fibroblasts in the tumor-stromal compartment makes them an optimal target for cancer immunotherapy. These cells are also the primary source of collagen type I, which contributes to decreased chemotherapeutic drug uptake in tumors and plays a significant role in regulating tumor sensitivity to a variety of chemotherapies. To specifically kill tumor-associated fibroblasts, we constructed an oral DNA vaccine targeting fibroblast activation protein (FAP), which is specifically overexpressed by fibroblasts in the tumor stroma. Through CD8+ T cell-mediated killing of tumor-associated fibroblasts, our vaccine successfully suppressed primary tumor cell growth and metastasis of multidrug-resistant murine colon and breast carcinoma. Furthermore, tumor tissue of FAP-vaccinated mice revealed markedly decreased collagen type I expression and up to 70% greater uptake of chemotherapeutic drugs. Most importantly, pFap-vaccinated mice treated with chemotherapy showed a 3-fold prolongation in lifespan and marked suppression of tumor growth, with 50% of the animals completely rejecting a tumor cell challenge. This strategy opens a new venue for the combination of immuno- and chemotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, depleting fibroblast activation protein (FAP)+ CAFs via a FAP vaccine decreases collagen density and improves chemoresistance in mouse models [99].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
The myofibroblast in wound healing and fibrocontractive diseases
Gabbiani, G. (2003) · The Journal of Pathology · doi:10.1002/path.1427 · Cited by 1,630
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Stromal Effects on Mammary Gland Development and Breast Cancer
Wiseman, B. S., & Werb, Z. (2002) · Science · doi:10.1126/science.1067431 · Cited by 923
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection
Baxter, L. T., & Jain, R. K. (1989) · Microvascular Research · doi:10.1016/0026-2862(89)90074-5 · Cited by 894
Large induction of keratinocyte growth factor expression in the dermis during wound healing
Werner, S., Peters, K. G., Longaker, M. T., Fuller-Pace, F., Banda, M. J., & Williams, L. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.6896 · Cited by 612
Park, J. E., Lenter, M. C., Zimmermann, R. N., Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36505 · Cited by 586
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.
Jain, R. K. (1990) · PubMed · Cited by 574
Scanlan, M. J., Raj, B. K., Calvo, B., Garin-Chesa, P., Sanz-Moncasi, M. P., Healey, J. H., Old, L. J., & Rettig, W. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5657 · Cited by 574
Apoptosis-targeted therapies for cancer
Reed, J. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00241-6 · Cited by 500
Tumor-induced immune dysfunction: the macrophage connection
Elgert, K. D., Alleva, D. G., & Mullins, D. W. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.64.3.275 · Cited by 426
Sica, A., Saccani, A., Bottazzi, B., Polentarutti, N., Vecchi, A., Van Damme, J., & Mantovani, A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.762 · Cited by 426
New insights into the role of extracellular matrix during tumor onset and progression
Pupa, S. M., Ménard, S., Forti, S., & Tagliabue, E. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10142 · Cited by 419
Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215234 · Cited by 415
Yang, Y.-A., Dukhanina, O. I., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J. D., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15333 · Cited by 404
Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215333 · Cited by 404
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth
Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., & Reisfeld, R. A. (2002) · Nature Medicine · doi:10.1038/nm1202-794 · Cited by 400
Transport of fluid and macromolecules in tumors
Baxter, L. T., & Jain, R. K. (1991) · Microvascular Research · doi:10.1016/0026-2862(91)90003-t · Cited by 368
Chemokines: signal lamps for trafficking of T and B cells for development and effector function
Kim, C. H., & Broxmeyer, H. E. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.1.6 · Cited by 342
Control of Apoptosis during Angiogenesis by Survivin Expression in Endothelial Cells
O'Connor, D. S., Schechner, J. S., Adida, C., Mesri, M., Rothermel, A. L., Li, F., Nath, A. K., Pober, J. S., & Altieri, D. C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64742-6 · Cited by 341
Dieu-Nosjean, M.-C., Vicari, A., Lebecque, S., & Caux, C. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.66.2.252 · Cited by 266
Dominant cell death induction by extramitochondrially targeted apoptosis‐inducing factor
LOEFFLER, M., DAUGAS, E., SUSIN, S. A., ZAMZAMI, N., MÉTIVIER, D., NIEMINEN, A., BROTHERS, G., PENNINGER, J. M., & KROEMER, G. (2001) · The FASEB Journal · doi:10.1096/fj.00-0388com · Cited by 241
Self-citationCheng, J. D., Dunbrack, R. L., Valianou, M., Rogatko, A., Alpaugh, R. K., & Weiner, L. M. (2002) · PubMed · Cited by 217
Tumors as elusive targets of T-cell-based active immunotherapy
Marincola, F. M., Wang, E., Herlyn, M., Seliger, B., & Ferrone, S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00116-9 · Cited by 202
Vitale, M., Rezzani, R., Rodella, L. F., Zauli, G., Grigolato, P., Cadei, M., Hicklin, D. J., & Ferrone, S. (1998) · PubMed · Cited by 174
Khorana, A. A., Ryan, C., Cox, C., Eberly, S. W., & Sahasrabudhe, D. M. (2003) · Cancer · doi:10.1002/cncr.11152 · Cited by 170
Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.
Singh, S., Ross, S. R., Acena, M., Rowley, D. A., & Schreiber, H. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.1.139 · Cited by 170
Kataki, A., Scheid, P., Piet, M., Marie, B., Martinet, N., Martinet, Y., & Vignaud, J.-M. (2002) · Journal of Laboratory and Clinical Medicine · doi:10.1067/mlc.2002.128317 · Cited by 166
CD40 and Dendritic Cell Function
O’Sullivan, B., & Thomas, R. (2003) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v23.i12.50 · Cited by 160
Lee, J., Fassnacht, M., Nair, S., Boczkowski, D., & Gilboa, E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2805 · Cited by 159
Tumor Rejection by Disturbing Tumor Stroma Cell Interactions
Ibe, S., Qin, Z., Schüler, T., Preiß, S., & Blankenstein, T. J. F. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.11.1549 · Cited by 149
Johnsen, A. K., France, J., Sy, M., & Harding, C. V. (1998) · PubMed · Cited by 131
Small polydispersed circular DNA (spcDNA) in human cells: association with genomic instability
Cohen, S., Regev, A., & Lavi, S. (1997) · Oncogene · doi:10.1038/sj.onc.1200917 · Cited by 125
Targeted Disruption of Mouse Fibroblast Activation Protein
Niedermeyer, J., Kriz, M., Hilberg, F., Garin‐Chesa, P., Bamberger, U., Lenter, M., Park, J., Viertel, B., Püschner, H., Mauz, M., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.1089-1094.2000 · Cited by 119
Boucher, Y., Brekken, C., Netti, P. A., Baxter, L. T., & Jain, R. K. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.705 · Cited by 112
Muris, J. J. F., Meijer, C. J. L. M., Cillessen, S. A. G. M., Vos, W., Kummer, J. A., Bladergroen, B. A., Bogman, M. J. J. T., MacKenzie, M. A., Jiwa, N. M., van Heukelom, L. H. S., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403240 · Cited by 100
Chemotherapy: friend or foe to cancer vaccines?
Emens, L. A., Machiels, J., Reilly, R. T., & Jaffee, E. M. (2001) · PubMed · Cited by 76
Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine
Luo, Y., Zhou, H., Mizutani, M., Mizutani, N., Reisfeld, R. A., & Xiang, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1033132100 · Cited by 76
Vascular endothelial growth factor and vascular targeting of solid tumors.
Brekken, R. A., & Thorpe, P. E. (2001) · PubMed · Cited by 73
TGF-Beta Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Ratliff, T. L. (2004) · The Journal of Urology · doi:10.1016/s0022-5347(05)61795-8 · Cited by 71
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth
Niethammer, A. G., Xiang, R., Becker, J. C., et al. (2002) · Nature Medicine · doi:10.1038/nm794 · Cited by 64
The Analysis of Convection and Diffusion in Capillary Beds
Leonard, E. F., & Jørgensen, S. B. (1974) · Annual Review of Biophysics and Bioengineering · doi:10.1146/annurev.bb.03.060174.001453 · Cited by 51
Immune responses to human tumors: development of tumor vaccines.
Platsoucas, C. D., Fincke, J. E., Pappas, J., Jung, W.-J., Heckel, M. C., Schwarting, R., Magira, E. E., Monos, D. S., & Freedman, R. S. (2003) · PubMed · Cited by 45
Munck, J. N., Riggi, M., Rougier, P. R., Chabot, G. G., Ramirez, L. H., Zhao, Z., Bognel, C., Ardouin, P., Herait, P., & Gouyette, A. (1993) · PubMed · Cited by 41
Tumor Rejection by Modulation of Tumor Stromal Fibroblasts
Schüler, T., Körnig, S., & Blankenstein, T. J. F. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030849 · Cited by 39
T-cell growth factors and the treatment of patients with cancer
Lotze, M. T. (1992) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(92)90040-u · Cited by 21
Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215234 · Cited by 21
THE HEALING SKIN WOUND: A NOVEL SITE OF ACTION OF THE CHEMOKINE C10
Kaesler, S., Regenbogen, J., Durka, S., Goppelt, A., & Werner, S. (2002) · Cytokine · doi:10.1006/cyto.2001.0981 · Cited by 17
Cited by
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
“A number of studies have implicated CAFs in the capability to limit the impact on tumor growth and progression of cancer cell apoptosis (Kalluri and Zeisberg, 2006; Loeffler et al., 2006; Pietras and Ostman, 2010).”
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
“cell-mediated immune response and further inhibit tumor growth and metastasis [330].”
BackgroundTurning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Metadata
- Authors
- Loeffler, M.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Loeffler, M.
- ORCID
- Loeffler, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1955-1962
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1481657
- OpenAlex
- W2002689409
- Cited by
- 633
- References
- 51
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 41 · 2023: 58 · 2022: 33 · 2021: 56 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 32 · 2016: 39 · 2015: 46 · 2014: 33 · 2013: 33 · 2012: 28
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health
- National Cancer Institute (CA 83856, R01CA083856)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer-associated fibroblasts, fibroblast activation protein, oral DNA vaccine, type I collagen, tumor stroma, chemosensitization, multidrug resistance, colon cancer, breast cancer, metastasis, chemoimmunotherapy
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Female, Fibroblasts, Membrane Proteins, Mice, Inbred BALB C, Neoplasms, Endopeptidases, Recombinant Fusion Proteins, Serine Endopeptidases, Survival Rate, Gelatinases, CD8-Positive T-Lymphocytes, Vaccines, DNA, Cancer Vaccines, Collagen Type I, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.